Sameer Doshi

Sameer Doshi

Auto-generated profile, based on publicly available information

Sameer Doshi

Amgen, Inc. Thousand Oaks California USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SDSameer Doshi
Sameer Doshi
PGPer Olsson Gisleskog
Per Olsson Gisleskog
YZYilong Zhang
Yilong Zhang
MZMin Zhu
Min Zhu
KOKelly S. Oliner
Kelly S. Oliner
JRJuan Jose Perez Ruixo
Juan Jose Perez Ruixo
Purpose: Rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor. In a randomized phase II study, trends toward improved survival were observed with rilotumumab (7.5 or 15 mg/kg) plus epirubicin, cisplatin, and capecitabine (ECX) versus placebo plus ECX in gastric/gastroesophageal junction (GEJ) cancer patients, especially in MET-positive patients. Here, we quantitatively characterized the longitudinal exposure–response [tumor growth (TG) and overall survival (OS)] relationship for rilotumumab. Experimental Design: Rilotumumab concentrations, tumor sizes, and survival time from the phase II study were pooled to develop a longitudinal exposure versus TG model and parametric OS model that explored predictive/prognostic/treatment effects (MET expression, rilotumumab exposure, relative tumor size). Model evaluation included visual predictive checks, nonparametric bootstrap, and normalized prediction distribution errors. Simulations were undertaken to predict the relationship between rilotumumab dose and OS. Results: Rilotumumab exhibited linear time-independent pharmacokinetics not affected by MET expression. The TG model adequately described tumor size across arms. A Weibull distribution best described OS. Rilotumumab exposure and change in tumor size from baseline at week 24 were predictive of OS. MET-positive patients showed shorter survival and responded better to rilotumumab than MET-negative patients. Simulations predicted a median (95% confidence interval) HR of 0.38 (0.18–0.60) in MET-positive patients treated with 15 mg/kg rilotumumab Q3W. Conclusions: Rilotumumab plus ECX demonstrated concentration-dependent effects on OS, influenced by MET expression, and tumor size in gastric/GEJ cancer patients. These findings support the phase II testing of rilotumumab 15 mg/kg every 3 weeks in MET-positive gastric/GEJ cancer (RILOMET-1; NCT01697072). Clin Cancer Res; 21(11); 2453–61. ©2015 AACR.

25 July 2012 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
DFDaniel J Freeman
Daniel J Freeman
KMKevin McDorman
Kevin McDorman
SOSelam Ogbagabriel
Selam Ogbagabriel
CKCarl Kozlosky
Carl Kozlosky
BYBing-Bing Yang
Bing-Bing Yang
RRRobert Radinsky
Robert Radinsky
Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue.

2 November 2019 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
JCJohn David Clements
John David Clements
MZMin Zhu
Min Zhu
MKMita Kuchimanchi
Mita Kuchimanchi
BTBianca Terminello
Bianca Terminello
SDSameer Doshi
Sameer Doshi
Background and objectives Blinatumomab (BLINCYTO®) is a novel bispecific T cell engager (BiTE®) approved in the USA for the treatment of relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) in children and adults, as well as minimal residual disease ALL in adults. This analysis characterized the population pharmacokinetics of intravenous blinatumomab in pediatric and adult patients. Methods A total of 2417 serum concentrations of blinatumomab from 674 patients, including adult (n = 628) and pediatric patients (n = 46), from eight clinical studies were analyzed. The impact of covariates on pharmacokinetic parameters were explored, and significant covariates were further evaluated using a simulation approach. Results Blinatumomab pharmacokinetics were described by a one-compartment linear model with first-order elimination, a clearance (CL) of 2.22 L/h, and a central volume of 5.98 L. A statistically significant effect of body surface area (BSA) on CL was observed. The smallest BSA of 0.37 m2 in the pediatric population was associated with a 63% reduction in blinatumomab systemic CL, relative to an adult patient with the median BSA (1.88 m2), supporting the use of BSA-based dosing in patients of lower bodyweight. The BSA effect was minimal, with a ≤ 25% change in CL over the range of BSA in adults, supporting no need for BSA-based dosing. Conclusions Blinatumomab pharmacokinetics were adequately described by a one-compartment linear model with first-order elimination. No covariates other than BSA on CL were identified as significant. BSA-based dosing should be considered for lightweight patients to minimize inter-subject variability in blinatumomab exposure.

24 May 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
LALubna Abuqayyas
Lubna Abuqayyas
PCPo-Wei Chen
Po-Wei Chen
MSMarcia Teixeira dos Santos
Marcia Teixeira dos Santos
JPJane R. Parnes
Jane R. Parnes
SDSameer Doshi
Sameer Doshi
BHBrett E. Houk
Brett E. Houk
Rozibafusp alfa (AMG 570) is a first‐in‐class bispecific IgG2‐peptide fusion designed to inhibit inducible T‐cell costimulator ligand (ICOSL) and B‐cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in two randomized, placebo‐controlled clinical studies: a phase Ia single ascending‐dose study (7–700 mg subcutaneously (s.c.)) in healthy subjects and a phase Ib multiple ascending‐dose study (70–420 mg s.c. every 2 weeks (q2w)) in patients with rheumatoid arthritis. Rozibafusp alfa exhibited nonlinear PK and dose‐related and reversible dual‐target engagement. Maximal reduction of naïve B cells from baseline (> 40%), reflective of BAFF inhibition, was achieved with rozibafusp alfa exposure (area under the concentration‐time curve from time 0 to time infinity (AUCinf) and AUC within a dosing interval from day 0 to day 14 (AUCtau)) above 51 and 57 days•μg/mL for the single‐dose (≥ 70 mg) and multiple‐dose studies (≥ 70 mg q2w), respectively. ICOSL receptor occupancy on circulating B cells, a surrogate PD end point for ICOSL inhibition, was directly related to drug concentration. PK/PD analysis showed > 90% RO at rozibafusp alfa ≥ 22.2 μg/mL (≥ 420‐mg single dose or ≥ 210 mg q2w multiple dose), with saturation occurring at higher drug concentrations. These results informed the design and dose selection of a phase IIb study assessing the safety and efficacy of rozibafusp alfa in patients with active systemic lupus erythematosus.

7 May 2018 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
MKMita Kuchimanchi
Mita Kuchimanchi
AGAnita Grover
Anita Grover
MEMaurice G. Emery
Maurice G. Emery
RSRansi Somaratne
Ransi Somaratne
SWScott M. Wasserman
Scott M. Wasserman
SDSameer Doshi
Sameer Doshi
Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia. The primary objective of this analysis was to characterize the population pharmacokinetics (popPK) and exposure–response relationship of evolocumab to assess if dose adjustment is needed across differing patient populations. Data were pooled for 5474 patients in 11 clinical studies who received evolocumab doses of 7–420 mg at various frequencies, either intravenously or subcutaneously. Evolocumab area under concentration–time curve from 8 to 12 weeks (AUCwk8–12) was simulated for individuals using the popPK model and was used to predict the LDL-C response in relation to AUCwk8–12. Evolocumab was eliminated through nonspecific (linear) and target-mediated (nonlinear) clearance. PopPK parameters and associated variabilities of evolocumab were similar to those of other monoclonal antibodies. The exposure–response model predicted a maximal 66% reduction in LDL-C from baseline to the mean of weeks 10 and 12 for doses of evolocumab 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. After inclusion of statistically significant covariates in an uncertainty-based simulation, LDL-C reduction from baseline at the mean of weeks 10 and 12 was predicted to be within 74% to 126% of the reference patient for all simulated patient groups. Evolocumab had nonlinear pharmacokinetics. The range of responses based on intrinsic and extrinsic factors was not predicted to be sufficiently different from the reference patient to warrant evolocumab dose adjustment.

3 February 2022 in Clinical Therapeutics
Verified
Journal Article
Open access
PDF file
SDSameer Doshi
Sameer Doshi
HWHui Wang
Hui Wang
VCVincent Chow
Vincent Chow
• ABP 501 (US: [adalimumab-atto]; EU: [adalimumab]) is an adalimumab biosimilar • Totality of evidence supported its approval • Population model assessed antidrug antibodies’ effect on pharmacokinetic parameters • Model-based evaluation confirmed pharmacokinetic similarity • Population modeling confirmed bioequivalence with reference product